12. SEGMENTS

3 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

SEGMENTS

12. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and Exosome Sciences, Inc., or ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Three Months Ended June 30,
	2019			2018
Revenues:
Aethlon	$	30,000		$	149,625
ESI		–			–
Total Revenues	$	30,000		$	149,625
Operating Losses:
Aethlon	$	(1,561,885	)	$	(1,066,530	)
ESI		(4,303	)		(30,742	)
Total Operating Loss	$	(1,566,188	)	$	(1,097,272	)
Net Losses:
Aethlon	$	(2,062,981	)	$	(1,121,634	)
ESI		(4,303	)		(30,742	)
Net Loss Before Non-Controlling Interests	$	(2,067,284	)	$	(1,152,376	)
Cash:
Aethlon	$	2,492,170		$	6,120,796
ESI		184			2,106
Total Cash	$	2,492,354		$	6,122,902
Total Assets:
Aethlon	$	2,932,721		$	6,451,635
ESI		184			2,106
Total Assets	$	2,932,905		$	6,453,741
Capital Expenditures:
Aethlon	$	886		$	–
ESI		–			–
Capital Expenditures	$	886		$	–
Depreciation and Amortization:
Aethlon	$	2,868		$	8,109
ESI		–			–
Total Depreciation and Amortization	$	2,868		$	8,109
Interest Expense:
Aethlon	$	(54,085	)	$	(55,104	)
ESI		–			–
Total Interest Expense	$	(54,085	)	$	(55,104	)